Last Updated: 31 July 2026
China Market Access: China Medical Device Registration Guidance for Overseas RA Teams
In order to file your medical device or IVD reagent with China’s national medical products administration NMPA and satisfy china medical device regulations, Morulaa as your APAC registration partner will handle your turnkey China Medical Device Registration solution for medical devices imported from overseas.
As Your China Medical Device Regulatory Consulting Partner, We Can Assist You With Medical Device Registration In China In The Following Ways
Determining the class and submission pathway: We will evaluate whether your product falls under Class I filing or Class II/III registration, including Class II/III registration for products from Hong Kong SAR, Macao and Chinese Taipei imported into China which adopt the same procedure as domestically produced products.
Preparing the Chinese dossier: We will prepare China-specific applications, including technical requirements, test reports, clinical evidence, labeling, and quality management system documents based on your overseas technical file.
Obtaining the China Medical Device registration certificate: Your domestic partner will be assisted in making online applications to the China FDA, responding to supplementary information requests from CMDE, and obtaining the NMPA medical device registration certificate so that your product can enter the Chinese market legally.
Maintaining the China registration certificate: We can help with annual quality system maintenance reports, UDI implementation, changes, renewals of the registration certificate due at the five-year interval and recalls of your devices in the Chinese market if problems arise.
China Medical Device Registration Is It Necessary to Appoint or Rely on a Distributor for NMPA Filing?
Deciding who manages your NMPA medical device registration certificate is crucial. A commercial distributor operates under the goals of marketing, warehousing, and shipping the products. The domestic agent within China manages the submission process, QMS annual self-inspection report to the provincial department of drugs, as well as post market activities related to the certificate. Through separation of regulatory relations from commercial ones, foreign manufacturers make sure that the China certificate remains independent and flexible regarding distribution options.
A system where the China certificate is managed by the commercial entity ties you up to just one commercial partner. With the domestic agent, you are able to operate with several distributors and have one spine for all renewals and changes.
According to China medical device regulations, the domestic agent remains active in relation to annual QMS reports till 31st of March, changing applications, renewals and recalls management. We manage this compliance burden for you so that your commercial team may concentrate on the demand.
How the National Medical Products Administration NMPA Separates Class I Filing From Class II and Class III Registration
China has a two level classification system for medical device registration in China covering imported medical devices and IVD reagents based on the degree of risk they pose. Class I medical devices and IVD reagents are subject to product filing with the national medical products administration NMPA. Meanwhile, Class II and Class III medical devices and IVD reagents are subject to product registration at the national level. The Center for Medical Device Evaluation reviews the application for clinical trials, supplemental reports, and renewals of imported Class II and Class III medical devices and IVD reagents and issues a China Medical Device Registration certificate.
Overview of Risk Categories for China Medical Device Regulatory Consulting
Product Filing Lower Risk (e.g., Class I)
Products subject to filing include lower risk medical devices and IVD with less regulatory control as compared to Class II and Class III counterparts.
Product Registration Moderate Risk (e.g., Class II)
Moderate-risk medical devices and IVD reagents that generally require a technical evaluation by the Center for Medical Device Evaluation (CMDE), Chinese dossier packages, and clinical/PTR-aligned testing reports to obtain an NMPA medical device registration certificate.
Product Registration Higher Risk (e.g., Class III)
Higher-risk medical devices and IVD reagents with greater clinical evidence requirements, testing reports, and potential QMS surveillance inspections. In vitro diagnostic reagents also feature additional batch and material annex requirements.
As your china medical device regulatory consulting team, Morulaa will develop the justification and regulatory strategy for product filing or registration category that your medical device or IVD will be classified into to avoid getting stuck during queries from the national medical products administration NMPA Center for Medical Device Evaluation.
What Must Sit in the Dossier for NMPA Medical Device Registration
All application documents must be submitted in Chinese through the online system. When it comes to interpretation, original language documents must accompany the submission for reference purposes and permission to use the literature you cite.
RA PRO TIP
Most of China’s delays are caused by the PTR and test report discrepancies. By making sure your PTR wording matches your samples that will undergo CMDE’s review prior to any response, you avoid the one time supplement request that will eat away at your one year response time.
Home Country Approval, Innovative Tracks, and Technical Files for Medical Device Registration in China
To secure an NMPA medical device registration for an imported medical device or IVD reagent, you usually need a valid marketing certificate issued by the relevant home-country regulatory authority, such as the US FDA clearance or CE certificate, or a marketing authorization of the product as non medical, if applicable. Exceptionally, it is not required for devices and diagnostics that actively fall under China’s innovative regulatory tracks.
For overseas RA teams with MDD, MDR, FDA, or other home-country files, our china medical device regulatory consulting workstreams streamline processing your dossier evidence for incorporation into the application. It rarely involves starting from scratch.
These typically include:
Domestic agent appointment documents and forms in Chinese
Technical document translation/adaptation to reflect the PTR, IFU, and label claims
Clinical evaluation or exemption dossier according to NMPA catalogues and predicates
QMS narrative and inspection preparation if requested by CFDI
Identification of the review pathways (Innovative, Priority, Emergency) that can be applied to your application
RA PRO TIP
Note that any supplementary evidence must be submitted in one off notification in the form of a single document in practice, RA teams should aim to provide it no later than 1 year from the initial application submission date or it will be returned by the NMPA. Gap analysis pre audit usually prevents such situations.
When Does China Expect Local Clinical Trials Under China Medical Device Regulations?
All applications shall undergo a scientific clinical evaluation, unless exemption can be granted on the basis of an NMPA adjusted catalogue. Exemption from clinical trials is typically granted for products that have a clearly defined mechanism of action, established design, proven manufacturing history, have a predicate device in clinical use for a considerable period of time with no serious adverse events, or have demonstrated safety through non-clinical or comparative means.
Safety must be demonstrated either through predicate comparison dossiers or local clinical trials, which must be conducted at an accredited institution in China in accordance with Good Clinical Practice (GCP) upon submission to the local provincial drug administration. Class III medical devices, considered high-risk, must be approved by the national medical products administration NMPA, can only be conducted in Tertiary A hospitals, and their approval is automatically revoked if no subjects have signed informed consent forms within three years from the start of trials.
As part of our china medical device regulatory consulting services, Morulaa will identify whether catalogue exemption, predicate comparison, or local clinical trials will be the most viable option that CMDE is likely to accept.
How Long Does China NMPA Review Take?
Statutory clock begins after the acceptance for evaluation by the competent authority. The competent authority shall review the dossier within 3 working days of receipt for acceptance. The evaluation clock stops when additional information, dossier supplementation, QMS corrective actions or expert consultations are undertaken, as well as field inspections. The time limits for re-submission of applications may not exceed the period of the initial evaluation by more than 50%
RA PRO TIP
Accelerated pathways are relevant upon qualification. Innovative Product Procedures involve the development of a specific CMDE pathway for novel technology protected by patent with significant clinical benefit. Priority Registrations are available in case of a rare disease, oncology, pediatric/geriatric gap or significant clinical need without any predicate. Emergency Registration involves simultaneous testing, QMS validation, and evaluation during public health emergencies.
Certificate Life, Changes, Fees, and Post Market Duties
Validity and renewal
Certified devices get the systematic certificate number that identifies the national jurisdiction of issuance, imported product indication, year of registration, risk classification, and product coding. Initial certificates remain valid for five years. The re-registration application should be submitted precisely six months before expiry date.
Changes
Any modifications to design, composition, production, or intended use require formal change registration. Non-substantial changes in the form of modification in registrant or domestic agent names and addresses should be registered within 30 days from the date of occurrence.
Fees and enforcement
The fee for registration is to be paid in full upon formal acceptance of application. Any failure to make payment within the specified limit will treat the application as voluntarily withdrawn. In the course of review, CMDE can ask CFDI to inspect manufacturing facilities. Production lines that have been suspended for one year or more require protocol for verification prior to restarting. Defective or non compliant distributed products trigger mandatory device recall and destruction or retrieval of inventory.
What the import and agent team needs to be ready for
Chinese labeling and IFU in accordance with china medical device regulations and registration claims.
UDI implementation in order to improve supply chain transparency.
Annual QMS audit report to be submitted by the domestic agent by 31 March.
Change and re registration calendar aligned with five year certificate validity period.
FAQs
What are the barriers for overseas manufacturers before NMPA reviews a medical device registration in China?
You cannot apply for registration from overseas. You need to appoint an agent in China, and also submit a marketing authorization certificate issued by the local competent authorities (FDA, CE, etc) indicating that the product has been approved for sale in the country of origin.
Can I register the product in China without home country approval?
Only if it is an innovative medical device in China. However, you need to provide proof that the product is not considered a medical device in the country of origin (proof of authorization to sell the product as a non medical device).
How many days does it take for a technical review of Class II and III?
The initial technical review for Class II medical devices takes up to 60 days while Class III medical devices take 90 days. For an additional supplement, the time of technical review is up to 60 days for both classes. From the beginning of the technical review to the issuance of certificates, it takes another 20 days for the NMPA administrative licensing and 10 days for the issuing of certificates.
Do NMPA’s inspectors organize overseas visits to the manufacturer’s site?
Yes. At the stage of technical review, the Center for Medical Device Evaluation can ask the State Food and Drug Administration’s overseas inspection department to inspect overseas manufacturers. This is mainly done for the design, production, and verification of test reports when self testing is applied.
Are there any additional requirements for registering Class III IVD reagents?
In addition to the basic requirements, for the Product Technical Requirements, an appendix of the main raw materials and manufacturing methods should be provided. Three different lots should be tested, and the tests should be done using reference materials according to Chinese national standards, if available.
How long is a China Medical Device Registration certificate valid for?
A registration certificate is valid for 5 years from the date of issuance. The renewal application must be submitted 6 months prior to the expiry date. In case of significant changes to the registered product (design, material, manufacturing process, indication, and function), the change registration must be made. If the changes are insignificant and do not affect the essence, the registrant or agent is obliged to make the update within 30 days.
When is a local clinical trial necessary?
A clinical study is mandatory for all medical devices, except those listed in the list of exempt medical devices by the NMPA. For the rest of the medical devices, either a dossier for predicate comparison or a clinical study in compliance with china medical device regulations and Good Clinical Practices in China should be provided. Clinical studies for Class III medical devices require the consent of the NMPA and should be performed in the appropriate medical facilities.
Why should we have an independent domestic agent instead of using a distributor?
An independent domestic agent will be in charge of the registration documentation and post-market surveillance. It is important to divide these responsibilities from the distribution. In this way, your China certificate will not be influenced if something happens with the distributor.